Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Prescribing has shifted: in the first quarter of 2025 Zepbound made up 60% of total weight-loss prescriptions in America, and 75% of new ones. Chart: The Economist Lilly has also been quicker to ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers ...

Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...

How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created ...

GLP-1 weight loss drugs — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound ... A hydration calculator can help you figure out your personal water needs.

Hims & Hers Health, Inc. navigates strong growth and partnerships despite rising competitive risks. Click here to read an ...

Amgen’s AMGN stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader ...

With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.